BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial
March 19, 2018 at 07:14 AM EDT
* EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL